Stifel Nicolaus Reaffirms Buy Rating for Krystal Biotech (NASDAQ:KRYS)

Stifel Nicolaus reaffirmed their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a $204.00 target price on the stock, up from their previous target price of $178.00.

Several other research analysts have also recently weighed in on the stock. Citigroup upped their price target on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a buy rating in a report on Tuesday, February 27th. Guggenheim upped their price target on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a buy rating in a report on Tuesday, February 27th. Finally, William Blair reaffirmed an outperform rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of Buy and a consensus price target of $164.22.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $158.53 on Tuesday. The company has a market cap of $4.52 billion, a P/E ratio of 1,981.87 and a beta of 0.85. Krystal Biotech has a 1 year low of $82.09 and a 1 year high of $189.97. The stock’s fifty day moving average price is $159.74 and its two-hundred day moving average price is $130.06.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.82. The firm had revenue of $42.14 million during the quarter, compared to the consensus estimate of $27.43 million. During the same period in the previous year, the company posted ($1.25) EPS. On average, analysts expect that Krystal Biotech will post 1.89 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CAO Kathryn Romano sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the transaction, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at $2,145,823.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The disclosure for this sale can be found here. Insiders have sold a total of 40,587 shares of company stock valued at $6,535,591 over the last 90 days. 14.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. TimesSquare Capital Management LLC bought a new position in shares of Krystal Biotech during the third quarter valued at about $14,272,000. Charles Schwab Investment Management Inc. grew its stake in shares of Krystal Biotech by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 179,780 shares of the company’s stock worth $20,854,000 after purchasing an additional 17,614 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Krystal Biotech by 40.7% in the third quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock worth $278,416,000 after purchasing an additional 693,852 shares during the last quarter. Trexquant Investment LP grew its stake in shares of Krystal Biotech by 8.8% in the third quarter. Trexquant Investment LP now owns 8,113 shares of the company’s stock worth $941,000 after purchasing an additional 657 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Krystal Biotech by 2.0% in the third quarter. Northern Trust Corp now owns 213,263 shares of the company’s stock worth $24,739,000 after purchasing an additional 4,129 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).